These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35257539)

  • 21. Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review.
    Di Bona D; Frisenda F; Albanesi M; Di Lorenzo G; Caiaffa MF; Macchia L
    Clin Exp Allergy; 2018 Nov; 48(11):1391-1401. PubMed ID: 30079619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.
    Tortajada-Girbés M; Bousquet R; Bosque M; Carrera Martínez JJ; Ibáñez MD; Moreira A; Nieto A; Plaza AM; Rivas C; Requena G; Sánchez-Solis M; Tabar A; Torres-Borrego J; Zapatero L
    Expert Rev Respir Med; 2018 Sep; 12(9):745-754. PubMed ID: 30141696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
    Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
    Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Perennial Allergen Immunotherapy in Allergic Rhinitis in Patients with/without Asthma: A-Randomized Controlled Real-Life Study.
    Ünal D
    Int Arch Allergy Immunol; 2020; 181(2):141-148. PubMed ID: 31914443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression.
    Forbush JT; Banks TA
    Ann Allergy Asthma Immunol; 2016 Sep; 117(3):335-7. PubMed ID: 27613470
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study.
    Pitrez PM; de Souza RG; Roncada C; Heinzmann-Filho JP; Santos G; Pinto LA; Jones MH; Stein RT
    Pediatr Pulmonol; 2017 Nov; 52(11):1408-1413. PubMed ID: 29027379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
    Tarraf HN; Masoud HH; Zidan M; Wahba B
    J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
    Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Efficacy of Allergen-Specific Immunotherapy from Patient and Physician Perspectives.
    Shin YS; Jung JW; Park JW; Choi JH; Kwon JW; Lee S; Kim JH; Lee SM; Ahn YM; Han MY;
    Yonsei Med J; 2019 May; 60(5):446-453. PubMed ID: 31016906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
    Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
    Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
    Rodrigo GJ; Neffen H
    Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omalizumab response in patients with asthma by number and type of allergen.
    Soong W; Yoo B; Pazwash H; Holweg CTJ; Casale TB
    Ann Allergy Asthma Immunol; 2021 Aug; 127(2):223-231. PubMed ID: 33838339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
    Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
    Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
    Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
    Pérez de Llano LA; Cosío BG; Domingo C; Urrutia I; Bobolea I; Valero A; Entrenas Costa LM; Quirce S; Barranco P; Marina Malanda N; Andrés LP; Alvarez-Gutiérrez FJ
    J Allergy Clin Immunol Pract; 2019; 7(7):2277-2283.e2. PubMed ID: 30677539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allergen-specific Immunotherapy for Inhalant Allergens in Children.
    Caffarelli C; Cangemi J; Mastrorilli C; Giannetti A; Ricci G
    Curr Pediatr Rev; 2020; 16(2):129-139. PubMed ID: 31642784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.